Headlines about NxStage Medical (NASDAQ:NXTM) have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. NxStage Medical earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 44.2900691671304 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern’s scoring:
- NxStage Medical, Inc. (NASDAQ:NXTM) Experiences Heavier than Average Trading Volume – Modern Readers (modernreaders.com)
- NxStage Medical, Inc. (NASDAQ:NXTM) Experiences Heavier than Usual Trading Volume – Highlight Press (highlightpress.com)
- INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of NxStage Medical, Inc. to Fresenius Medical Care for $30 Per Share is Fair to Shareholders (finance.yahoo.com)
- NxStage Medical, Inc. (NXTM) Expected to Announce Quarterly Sales of $102.79 Million (americanbankingnews.com)
- NxStage Medical, Inc. (NXTM) SVP Winifred L. Swan Sells 3,500 Shares (americanbankingnews.com)
NxStage Medical (NXTM) opened at 29.25 on Friday. NxStage Medical has a 52 week low of $20.45 and a 52 week high of $30.80. The company has a 50-day moving average price of $25.63 and a 200 day moving average price of $25.95. The company’s market cap is $1.93 billion.
NxStage Medical (NASDAQ:NXTM) last posted its earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.03). NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The firm had revenue of $92.20 million during the quarter, compared to the consensus estimate of $96.47 million. During the same quarter last year, the firm earned ($0.03) EPS. The firm’s revenue for the quarter was up .0% on a year-over-year basis. On average, equities research analysts forecast that NxStage Medical will post ($0.04) EPS for the current fiscal year.
A number of research analysts have recently commented on the company. William Blair cut NxStage Medical from an “outperform” rating to a “market perform” rating in a research note on Monday, August 7th. Zacks Investment Research raised NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Thursday, August 10th. Craig Hallum assumed coverage on NxStage Medical in a research note on Tuesday, June 27th. They set a “buy” rating and a $32.00 target price on the stock. Canaccord Genuity cut NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 target price on the stock. in a research note on Monday, August 7th. Finally, BidaskClub cut NxStage Medical from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. One research analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $30.29.
COPYRIGHT VIOLATION NOTICE: This story was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/08/19/nxstage-medical-nasdaqnxtm-receiving-somewhat-favorable-press-coverage-accern-reports-updated-updated.html.
In other NxStage Medical news, President Joseph E. Turk, Jr. sold 1,000 shares of the business’s stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $25.19, for a total value of $25,190.00. Following the completion of the transaction, the president now owns 75,903 shares in the company, valued at $1,911,996.57. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $29.21, for a total transaction of $102,235.00. Following the completion of the transaction, the senior vice president now owns 16,270 shares of the company’s stock, valued at approximately $475,246.70. The disclosure for this sale can be found here. Insiders sold a total of 53,900 shares of company stock valued at $1,429,518 in the last quarter. 4.70% of the stock is owned by insiders.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
What are top analysts saying about NxStage Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NxStage Medical Inc. and related companies.